Can I Take Ashwagandha with Metformin?

Metformin (biguanide class, brand names include Glucophage) is an FDA-approved first-line medication for type 2 diabetes. Ashwagandha (Withania somnifera, also called Indian ginseng) is an adaptogenic herbal supplement sold over the counter, not an FDA-approved drug, and not standardized the way a prescription product is. No dedicated human trial has tested the two together, so everything below is built from single-agent evidence and pharmacology reasoning rather than from a combination study.

What kind of interaction exists between ashwagandha and metformin?

The interaction is pharmacodynamic, not pharmacokinetic. There is no well-documented evidence that ashwagandha meaningfully inhibits or induces the cytochrome P450 enzymes or the renal transporters (OCT1, OCT2, MATE1) that govern metformin's absorption and clearance. That means ashwagandha is not expected to raise or lower metformin blood levels the way a drug such as cimetidine can. This absence of a pharmacokinetic mechanism is consistent across the general herb-drug interaction literature, though a study designed specifically to test ashwagandha's effect on metformin transporters has not been identified.

The concern instead is that both substances affect blood glucose through different, and potentially additive, pathways.

How metformin lowers glucose

Metformin's accepted mechanism is activation of AMP-activated protein kinase (AMPK) in the liver, which suppresses hepatic glucose output and improves peripheral insulin sensitivity. As monotherapy at standard doses, it produces a clinically established HbA1c reduction, and this is well established through decades of trial data and its FDA-approved labeling.

How ashwagandha may affect blood sugar

Small randomized trials in patients with type 2 diabetes or with metabolic stress have reported that ashwagandha root extract, typically 300 to 600 mg per day, lowers fasting blood glucose compared with placebo over 8 to 12 weeks. The proposed mechanisms include enhanced insulin secretion, increased GLUT4 glucose-transporter activity in skeletal muscle, and reduced oxidative stress. These are single-agent trials with small sample sizes and short durations; the source materials reviewed here cite a specific milligram-per-deciliter reduction from one trial, but that figure could not be verified against the primary paper during this review and should be treated as unconfirmed until checked directly against the published study rather than repeated as an established number.

What "additive pharmacodynamic effect" means practically

When two substances both lower glucose, the combined effect can exceed what either produces alone. For a patient on metformin monotherapy whose HbA1c runs well above target, this might be a welcome effect. For a patient already at or near target, or one taking a sulfonylurea or insulin alongside metformin, adding ashwagandha introduces a real, if unquantified, risk of pushing fasting glucose into hypoglycemic range.

The cortisol question: does it matter for metformin users?

Ashwagandha is classified as an adaptogen, a substance proposed to modulate the body's stress-hormone response. Its most consistently studied human effect is a reduction in serum cortisol, reported in small randomized trials. Cortisol raises blood glucose by stimulating hepatic gluconeogenesis and blunting insulin signaling at the receptor level, so a cortisol-lowering effect is biologically plausible as a second route by which ashwagandha could reduce glucose, working through the hypothalamic-pituitary-adrenal axis rather than through AMPK or insulin secretion directly.

This is a plausible mechanism, not an established clinical effect in combination with metformin. Patients whose hyperglycemia is stress-driven may theoretically see a larger glucose response when adding ashwagandha, but this has not been tested directly.

Ashwagandha and the thyroid: a separate watch-point

Small randomized trials have reported that ashwagandha root extract increases serum T3 and T4 compared with placebo over roughly 8 weeks. Metformin itself has no direct thyroid pharmacology, so this is not a metformin-specific interaction, but it is relevant to the overlapping patient population. Hypothyroidism is common enough among people with type 2 diabetes that many metformin users also take levothyroxine. Adding ashwagandha to a levothyroxine-plus-metformin regimen could theoretically raise circulating thyroid hormone and produce symptoms of hyperthyroidism, such as palpitations, insomnia, unintended weight loss, or new glucose variability.

If you take levothyroxine and are considering ashwagandha, a reasonable step is to recheck TSH and free T4 six to eight weeks after starting, and to report new palpitations or unexplained weight change to your prescriber.

Does ashwagandha affect testosterone, and does that matter for metformin users?

Some small trials in men with fertility concerns have reported testosterone increases with ashwagandha supplementation. Metformin is sometimes used off-label for polycystic ovary syndrome (PCOS), a condition where elevated androgens are already a concern. Evidence for a meaningful testosterone effect in women is thin, but the theoretical concern is worth raising with a prescriber for a woman with PCOS considering ashwagandha alongside metformin. For men with type 2 diabetes and obesity-related low testosterone, a modest increase is plausible but this is not established as clinically meaningful, and ashwagandha is not a treatment for hypogonadism.

Is there a required dose-separation window?

No mandatory separation window applies to this combination. Because the concern is pharmacodynamic rather than pharmacokinetic, spacing the two by an hour or two would not change the underlying glucose-lowering overlap. Taking both with food is a reasonable default: metformin is better tolerated with meals to reduce gastrointestinal side effects, and ashwagandha is also generally taken with food.

What the evidence base actually looks like

A systematic review of ashwagandha in diabetes and metabolic stress populations, pooling several small randomized trials, reported reductions in fasting glucose and HbA1c compared with placebo. This is the strongest tier of evidence available for ashwagandha's glucose effect, but it remains a small, short-duration evidence base by the standards applied to prescription antidiabetic drugs, and the specific effect sizes reported in secondary summaries should be verified against the original trials before being used to counsel an individual patient.

Evidence-status interaction assessment

Who should be most cautious about this combination?

Patients already near glycemic target. If a recent HbA1c is close to target on metformin alone, adding a supplement with an independent glucose-lowering effect raises the plausible risk of overnight or fasting hypoglycemia. Checking fasting glucose for the first few weeks after starting is a reasonable precaution.

Patients on multi-drug regimens. Combining metformin with a sulfonylurea, an SGLT2 inhibitor, or insulin already raises baseline hypoglycemia risk. Adding ashwagandha to these regimens without a prescriber's input is not advisable. The American Diabetes Association's Standards of Care describes hypoglycemia as a central limiting factor in diabetes management generally, which is the relevant guideline-level context here (see the current ADA Standards of Medical Care, diabetesjournals.org).

Patients with thyroid disease or autoimmune conditions. Ashwagandha has documented immune-stimulating activity in preclinical work. Patients with autoimmune thyroid disease, lupus, rheumatoid arthritis, or multiple sclerosis should discuss ashwagandha with a physician before use, since immune stimulation could theoretically affect disease activity.

Pregnant patients. Some patients use metformin for gestational diabetes. Ashwagandha has reported abortifacient effects in animal studies and is generally considered contraindicated in pregnancy. This combination should be avoided during pregnancy.

Monitoring approach if you decide to combine both

• Before starting ashwagandha: fasting glucose, HbA1c, and TSH/free T4 if on levothyroxine or with a thyroid history.
• First few weeks: home fasting glucose checks, more frequent if you have any history of hypoglycemia; log any reading below 70 mg/dL and report it.
• 8 to 12 weeks: repeat fasting glucose and HbA1c; discuss any meaningful drop with your prescriber, since it may warrant a metformin dose review rather than being attributed only to the medication.
• 6 to 8 weeks, thyroid subgroup: recheck TSH and free T4 if on levothyroxine.
• Ongoing: continue HbA1c monitoring on the schedule your prescriber uses for your overall diabetes management, per current ADA guidance.

Practical notes on ashwagandha dosing

Most trials examining glucose or cortisol outcomes have used 300 to 600 mg per day of root extract, generally standardized to a stated withanolide percentage (branded extracts such as KSM-66 or Sensoril are common in trials). Doses above roughly 1,000 mg per day have not shown clearly greater glycemic benefit in the available small trials, and gastrointestinal side effects such as nausea or loose stools become more common at higher doses. Trials showing HbA1c benefit generally ran at least 12 weeks, so a reasonable expectation is that 8 to 12 weeks are needed before judging whether the supplement is doing anything measurable to your glucose control.

What a general drug-interaction database says

General interaction resources typically classify the ashwagandha-metformin combination as a moderate interaction based on the theoretical risk of additive hypoglycemic effects, without flagging it as contraindicated and without identifying a pharmacokinetic mechanism. This is consistent with the mechanistic picture described above: a plausible additive effect on glucose, no known effect on metformin's absorption or clearance.

Talking to your doctor or pharmacist

Bring the specific product label so your prescriber can see the extract type, standardization, and dose. Ask them to review your most recent HbA1c and fasting glucose trend before you start. If you are already taking ashwagandha and have not mentioned it, bring it up at your next visit: a change in glucose control that looks like it came from a metformin dose adjustment may actually reflect the supplement.

Evidence boundary

Established: metformin's glucose-lowering mechanism and its role as an FDA-approved first-line diabetes treatment. Established, with caveats about trial size and duration: ashwagandha has an independent glucose-lowering effect in small randomized trials, and no pharmacokinetic interaction with metformin has been identified. Plausible but unproven: that combining the two produces a clinically significant additive glucose drop, that ashwagandha's cortisol-lowering effect adds a second glucose-lowering pathway in metformin users, and that thyroid or testosterone effects meaningfully change outcomes for metformin users on levothyroxine or with PCOS. Not established: the actual magnitude of any additive glucose effect in a person taking both substances together, because no dedicated combination trial has been published as of this review.

References

The claims above draw on general pharmacology of metformin (AMPK activation, hepatic glucose output, renal transporter clearance), small randomized trials of ashwagandha in diabetes and metabolic-stress populations, and general adaptogen and thyroid-hormone literature. Several specific figures inherited from earlier source material (an exact milligram-per-deciliter glucose reduction, an exact percentage cortisol reduction, an exact percentage testosterone increase) could not be verified against a confirmed primary paper during this review and have been described qualitatively rather than repeated as fixed numbers. Before this article is published, a qualified reviewer should locate and cite the specific primary trials for each numeric claim, or the claims should remain qualitative.

• American Diabetes Association Professional Practice Committee, Standards of Care in Diabetes (current edition): https://diabetesjournals.org/care/issue/47/Supplement_1
• MedlinePlus / National Institutes of Health, general drug and supplement information: https://nih.gov
• PubMed, for locating and verifying the specific ashwagandha trials referenced qualitatively above: https://pubmed.ncbi.nlm.nih.gov/